Tin tức & Cập nhật

The two-drug regimen dolutegravir plus lamivudine (DTG/3TC) is as good as 3- or 4-drug antiretroviral therapy (ART) regimens at keeping viral load suppressed while helping avoid hepatitis B virus (HBV) reactivation in people living with HIV-1 who have past exposure to HBV but no immunity, according to a post hoc analysis of five phase 3/3b studies.

A substudy of the phase III FLAIR study has found comparable efficacy and pharmacokinetics for cabotegravir (CAB) plus rilpivirine (RPV) via subcutaneous (SC) administration relative to those via intramuscular (IM) gluteal injections among virally suppressed individuals living with HIV-1.

Perioperative pembrolizumab plus chemotherapy confers survival benefit in individuals with locally advanced gastric and gastroesophageal junction (G/GEJ) cancer in the final analysis of the phase III KEYNOTE-585 trial.